How Zomedica (NYSE American: ZOM) Is Changing the Veterinary Industry with Its Cutting-Edge Diagnostics and Therapeutics

Zomedica (NYSE American: ZOM) is revolutionizing veterinary health care with a focus on addressing unmet needs through its expanding product portfolio of innovative diagnostics and medical devices designed to improve pet health as well as productivity and practice profitability for veterinarians. With modest cash burn and a strong balance sheet, including $156 million cash, cash equivalents, and available-for-sale securities as of September 30, 2022, Zomedica is well-positioned to fund both organic growth and acquisitions. Visit ZomedicaInfo.com to learn more. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Zomedica (ZOM) is a client of RedChip Companies, Inc. ZOM agreed to pay RedChip Companies, Inc. a $9,500 monthly cash fee, beginning in January 2024, for six months of RedChip investor awareness services. ZOM also agreed to pay RedChip a one-time one-hundred-thousand dollar fee for a 19-day national TV ad campaign scheduled to air weekdays from November 15 through December 11, 2023.   For full disclosure, visit RedChip.com/disclosures.